MANAGEMENT GUIDELINES FOR HEALTH-CARE WORKERS EXPOSED TO BLOOD AND BODY-FLUIDS

被引:9
作者
GO, GW
BARAFF, LJ
SCHRIGER, DL
机构
[1] Emergency Medicine Center, the Department of Medicine, UCLA School of Medicine, Los Angeles, CA
[2] Emergency Medicine Center, the Department of Pediatrics, UCLA School of Medicine, Los Angeles, CA
关键词
BODY FLUIDS; ACCIDENTAL EXPOSURE; BLOOD; HEPATITIS; HIV;
D O I
10.1016/S0196-0644(05)81078-9
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The purpose of this article is to propose specific management guidelines for the immediate emergency department and subsequent occupational health treatment of health care workers (HCWs) following accidental exposures to blood or body fluids. These guidelines are based on a collective review of the literature and the recommendations of the Advisory Committee on Immunization Practices (ACIP) and authorities expert in this knowledge domain. Guidelines are needed to assure appropriate treatment and coordinated efforts by ED and occupational health providers. Although numerous infections can potentially be transmitted by exposure to blood and body fluids, these guidelines are intended only for evaluation and postexposure prophylaxis of hepatitis B, hepatitis C, and infection with HIV.
引用
收藏
页码:1341 / 1350
页数:10
相关论文
共 117 条
[101]  
Francavilla, Cadrobbi, Scaggiante, Et al., Surveillance on occupational exposure to HIV among health-care workers in Italy, V International Conference on AIDS, (1989)
[102]  
Henderson, HIV-1 in the health-care setting, Principles and Practice of Infectious Disease, (1990)
[103]  
Kelen, Fritz, Qagish, Et al., Unrecognized human immunodeficiency vines infection in emergency department patients, N Engl J Med, 318, pp. 1645-1650, (1988)
[104]  
Mitsuya, Weinhold, Furman, Et al., 3′-Azido-3′-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus in vitro, Proc Natl Acad Sci (USA), 82, pp. 7096-7100, (1985)
[105]  
Fischl, Richman, Grieco, Et al., The efficacy of azidovudine in the treatment of patients with AIDS and AIDS-related complex: A double blind, placebo-controlled trial, N Engl J Med, 317, pp. 185-191, (1987)
[106]  
Richman, Fischl, Grieco, Et al., The toxicity of azidovudine in the treatment of patients with AIDS and AIDS-related complex: A double blind, placebo-controlled trial, N Engl J Med, 317, pp. 192-197, (1987)
[107]  
Yarchoan, Klecker, Weinhold, Et al., Administration of 3′-Azido-3′-deoxythymidine, an inhibitor of HTLV III/LAV replication, to patients with AIDS or AIDS-related complex, Lancet, 1, pp. 575-580, (1986)
[108]  
Centers for Disease Control, Management of occupational exposure to HIV: Including considerations regarding post-exposure use of zidovudine, MMWR, 39, pp. 1-14, (1990)
[109]  
Sacks, Rose, Zidovudine prophylaxis for needlestick exposure to human immunodeficiency virus: A decision analysis, J Gen Intern Med, 5, pp. 132-137, (1990)
[110]  
Ruprecht, O'Brien, Rossoni, Et al., Suppression of mouse viremia and retroviral disease by 3′-Azido-3′-deoxythymidine, Nature, 323, pp. 467-469, (1986)